Back to Search Start Over

T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation

Authors :
Giacomo Oliveira
Chiara Bonini
Domenico Ghio
Catia Traversari
Sergio Fracchia
Alessandro Del Maschio
Alessandro Aiuti
Fabio Ciceri
Claudio Bordignon
Corrado Soldati
Jacopo Peccatori
Luca Vago
Maria Teresa Lupo Stanghellini
Raffaella Greco
Attilio Bondanza
Matteo Del Fiacco
Maddalena Noviello
Immacolata Brigida
Vago, L
Oliveira, G
Bondanza, Attilio
Noviello, M
Soldati, C
Ghio, D
Brigida, I
Greco, R
Stanghellini Mt, Lupo
Peccatori, J
Fracchia, S
Del Fiacco, M
Traversari, C
Aiuti, Alessandro
DEL MASCHIO, Alessandro
Bordignon, Claudio
Ciceri, Fabio
Bonini, MARIA CHIARA
Source :
Blood. 120:1820-1830
Publication Year :
2012
Publisher :
American Society of Hematology, 2012.

Abstract

The genetic modification of T cells with a suicide gene grants a mechanism of control of adverse reactions, allowing safe infusion after partially incompatible hematopoietic stem cell transplantation (HSCT). In the TK007 clinical trial, 22 adults with hematologic malignancies experienced a rapid and sustained immune recovery after T cell-depleted HSCT and serial infusions of purified donor T cells expressing the HSV thymidine kinase suicide gene (TK+ cells). After a first wave of circulating TK+ cells, the majority of T cells supporting long-term immune reconstitution did not carry the suicide gene and displayed high numbers of naive lymphocytes, suggesting the thymus-dependent development of T cells, occurring only upon TK+-cell engraftment. Accordingly, after the infusions, we documented an increase in circulating TCR excision circles and CD31(+) recent thymic emigrants and a substantial expansion of the active thymic tissue as shown by chest tomography scans. Interestingly, a peak in the serum level of IL-7 was observed after each infusion of TK+ cells, anticipating the appearance of newly generated T cells. The results of the present study show that the infusion of genetically modified donor T cells after HSCT can drive the recovery of thymic activity in adults, leading to immune reconstitution. (Blood. 2012;120(9):1820-1830) The genetic modification of T cells with a suicide gene grants a mechanism of control of adverse reactions, allowing safe infusion after partially-incompatible Hematopoietic Stem Cell Transplantation (HSCT). In the TK007 clinical trial 22 adults with hematologic malignancies experienced a rapid and sustained immune recovery after T cell-depleted HSCT and serial infusions of purified donor T cells expressing the Herpes Simplex Virus Thymidine Kinase suicide gene (TK(pos) cells). After a first wave of circulating TK(pos) cells, the majority of T cells supporting long-term immune reconstitution did not carry the suicide gene and displayed high numbers of naïve lymphocytes, suggesting the thymus-dependent development of T cells, occurring only upon TK(pos) cell engraftment. Accordingly, after the infusions we documented an increase in circulating T cell Receptor Excision Circles and CD31+ recent thymic emigrants, and a substantial expansion of the active thymic tissue at chest tomography scans. Interestingly, a peak in the serum level of interleukin-7 was observed after each infusion of TK(pos) cells, anticipating the appearance of newly generated T cells. Taken together, our data show that the infusion of genetically modified donor T cells after transplantation can drive the recovery of thymic activity in adults, leading to immune reconstitution.

Details

ISSN :
15280020, 00064971, and 18201830
Volume :
120
Database :
OpenAIRE
Journal :
Blood
Accession number :
edsair.doi.dedup.....41849e3c1bbad57309f383b11799bdcb